GSK shares hit 3-month high as Q2 earnings beat forecasts, driven by strong vaccine sales and pipeline investment.

GSK's shares rose to a three-month high after the company reported better-than-expected second-quarter results, with revenue up 5% to £8.41 billion and adjusted earnings per share increasing 9% to 50.5p. Vaccine sales grew 8%, notably with Shingrix and respiratory syncytial virus vaccine Arexvy outperforming expectations. Specialty Medicines also saw strong growth, while General Medicines declined. GSK reaffirmed its full-year guidance and announced a three-year restructuring plan targeting £1.9 billion in annual savings by 2029, with increased investment in research and development and a significant boost in phase III trial starts. Despite a statutory operating profit drop due to impairment charges, the company declared a 17p dividend, signaling confidence in its growth strategy.